STOCK TITAN

Amarin - AMRN STOCK NEWS

Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.

Amarin Corporation plc (AMRN) delivers innovative cardiovascular therapeutics through advanced lipid science, anchored by its FDA-approved therapy VASCEPA®. This page provides direct access to official company announcements, clinical research updates, and regulatory developments.

Investors and healthcare professionals will find curated press releases covering drug approvals, global expansion efforts, and peer-reviewed study results. Key updates include milestones from the landmark REDUCE-IT trial, intellectual property developments, and strategic partnerships enhancing patient access to cardiovascular care solutions.

All content is sourced from Amarin's corporate communications, ensuring accuracy and timeliness. Bookmark this page for streamlined tracking of AMRN's progress in addressing persistent cardiovascular risk through scientifically validated therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
Rhea-AI Summary
Amarin Corporation announces the compensation program for its new President and CEO, Patrick Holt. The majority of Holt's total target compensation is tied to the creation of shareholder value through stock options. He will be issued a one-time grant of stock options to purchase up to 5,000,000 shares, subject to performance-based vesting with share price hurdles ranging from $2.50 to $15.00. Holt has also agreed to purchase $300,000 worth of Amarin shares in the open market using personal funds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.48%
Tags
management
-
Rhea-AI Summary
Amarin Corporation has announced an organizational restructuring program to enhance shareholder value. The restructuring plan includes cost-saving measures of approximately $40 million annually, focusing on maximizing cash flow in the U.S., redesigning the commercial infrastructure in Europe, and expanding international partnerships. Preliminary Q2 2023 earnings results show a decrease in product revenue compared to the previous quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.48%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
conferences
-
Rhea-AI Summary
Amarin Corporation's commercial partner in China, EddingPharm, has received regulatory approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. EddingPharm is now preparing for the commercial launch of VASCEPA in China by year-end. The approval comes as cardiovascular disease accounts for a significant number of deaths in China, and the demand for cardiovascular medications is expected to increase in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
Amarin

Nasdaq:AMRN

AMRN Rankings

AMRN Stock Data

197.78M
20.55M
1.63%
18.07%
4.08%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2